{"id":629,"date":"2001-07-01T12:00:00","date_gmt":"2001-07-01T10:00:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2001\/sind-die-grenzen-der-medikamentoesen-reperfusionstherapie-beim-akuten-myokardinfarkt-erreicht-die-gusto-v-studie"},"modified":"2001-07-01T12:00:00","modified_gmt":"2001-07-01T10:00:00","slug":"sind-die-grenzen-der-medikamentoesen-reperfusionstherapie-beim-akuten-myokardinfarkt-erreicht-die-gusto-v-studie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2001\/sind-die-grenzen-der-medikamentoesen-reperfusionstherapie-beim-akuten-myokardinfarkt-erreicht-die-gusto-v-studie","title":{"rendered":"Sind die Grenzen der medikament\u00f6sen Reperfusionstherapie beim akuten Myokardinfarkt erreicht? Die GUSTO-V-Studie"},"content":{"rendered":"<p>Die GUSTO-V-Studie (urspr\u00fcnglich: Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) ist mit 16588 eingeschlossenen Patienten an 820 Studienzentren in 20 L\u00e4ndern eine der gr\u00f6\u00dften jemals durchgef\u00fchrten prospektiven Studien (Lancet 2001, 357, 1905). Die beiden Firmen Centocor und Eli Lilly haben enorme finanzielle und logistische Mittel aufgewendet, um ein neues Thrombolyse-Schema [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die GUSTO-V-Studie (urspr\u00fcnglich: Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) ist mit 16588 eingeschlossenen Patienten an 820 Studienzentren in 20 L\u00e4ndern eine der gr\u00f6\u00dften jemals durchgef\u00fchrten prospektiven Studien (Lancet 2001, 357, 1905). Die beiden Firmen Centocor und Eli Lilly haben enorme finanzielle und logistische Mittel aufgewendet, um ein neues Thrombolyse-Schema [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1464,730,729,1465,71,65,372,369,727],"class_list":["post-629","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-abciximab","tag-gp-iib-iiia-rezeptor-antagonisten","tag-gp-iib-iiia-rezeptor-blocker","tag-gusto-v-studie","tag-herzinfarkt","tag-myokardinfarkt","tag-reteplase","tag-rpa","tag-thrombozytenaggregationshemmer"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/629","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=629"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/629\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=629"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=629"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=629"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}